[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8, Issue 4 (7-2017) ::
Caspian J Intern Med 2017, 8(4): 276-281 Back to browse issues page
Antibiotic resistance status and its costs in hematological patients: A two-year analysis
Habip Gedik *
Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, İstanbul, Turkey , habipgedik@yahoo.com
Abstract:   (7075 Views)

Background: Most frequently, empirical antibiotic therapy is immediately administered for patients with febrile neutropenia (FN). In this study, its aim was to assess the antibiotic resistance status and the cost of antibacterial agents in FN patients associated with hematological malignancies.
Methods: The cost of antibacterial agents used in FN episodes in patients with hematologic neoplasms followed-up at the Department of Hematology from November 2010 to November 2012 were analyzed retrospectively.
Results: In the study period, 15 of 141 patients who were admitted to the hematology ward and ineligible for the study criteria were excluded. In total, 282 febrile episodes of 126 consecutive patients with neutropenia were retrospectively investigated. Imipenem was found to be the most commonly used among the antibacterial drugs as 1.16 patient daily dose (PDD)/100 patient-days, 117.16 is the mean defined daily dose (DDD) per month and US $73264.66 total cost per year, followed by meropenem, cefoperazone-sulbactam, and linezolid.
Conclusion: Choosing noncarbapenem-based antibacterial therapy for empirical treatment of FN until the growth of microorganisms and switching to carbapenem therapy subsequent to new radiological, or microbiological, or/ and clinical findings, the appropriate vancomycin use may decrease the cost of antibacterial agents in the treatment of FN episodes in patients with hematologic malignancies contributing to antimicrobial stewardship.

Keywords: Hematologic neoplasms, Febrile neutropenia, Cost analysis, Anti-bacterial agents, Drug resistance
Full-Text [PDF 478 kb]   (1271 Downloads)    
Type of Study: Original Article | Subject: Infectious Diseases
Received: 2016/06/20 | Accepted: 2017/04/29 | Published: 2017/09/11
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Gedik H. Antibiotic resistance status and its costs in hematological patients: A two-year analysis. Caspian J Intern Med. 2017; 8 (4) :276-281
URL: http://caspjim.com/article-1-788-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 8, Issue 4 (7-2017) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4419